Barclays starts CVS Group at “equal weight,” Australia deals miss capital hurdles

Barclays initiated coverage of CVS Group at 'equal weight' with a 1,340 pence price target vs the 1,182 pence share price on March 19 (≈13% upside). Barclays estimates post-tax returns on fiscal 2024/25 Australian acquisitions of 6.9% and 8.6% versus cost of capital of 10.2% and 9.7%, while the H1 FY26 cohort is estimated at 12.3% vs a 9.2% cost of capital, highlighting sub‑cost‑of‑capital earlier deals and elevated execution risk (including the Australia MD departure and a CMA probe). Barclays forecasts adjusted EPS of 83.8p in FY26 rising to 110.4p in FY28 (CAGR 11.3% from FY25), and sets upside/downside cases at 1,570p/1,075p; it also discloses liquidity‑provider status and non‑IB fees from CVS.

Analysis

CVS’s acquisition model is facing a structural headwind: sellers appear to prefer partnership/roll-up structures and private equity backers are executing faster with much higher EBITDA growth. That dynamic forces CVS either to overpay to win assets or accept a slower, less attractive pipeline — both outcomes compress ROIC given an elevated cost of capital environment and make near-term margin improvement dependent on hard-to-realize earn-outs and synergies over 12–36 months.

Regulatory and execution timing are the primary catalysts and risk multipliers. The CMA calendar creates a discrete event around spring 2026 that can swing M&A optionality and stock volatility; operationally, leadership churn in growth geographies (Australia) raises the probability of missed targets and potential impairment reviews within 6–18 months as higher financing costs crystallize. Rising rates are the hidden arbiter: deals signed under a lower-rate regime look meaningfully worse on an IRR basis today, increasing the chance of either aggressive cost cutting or write-downs if organic uplift misses.

Second-order effects favor competitors with asset-light or partnership models and scale in higher-margin services (preventive care, diagnostics): these players will be able to cherry-pick accretive practices and lift multiples while CVS’s balance sheet and wholly-owned model act as a constraint. Conversely, private-equity-backed consolidators that can deploy leverage are positioned to widen the gap in ROIC over the next 12–36 months unless CVS pivots its deal structure or secures regulatory clarity that opens a faster, accretive M&A runway.

Key Decisions for Investors

• 6–12 month short CVSG.L (equity) — tactically size 2–4% notional. Rationale: limited near-term M&A optionality + execution risk; target asymmetric downside ~20–30% vs stop-loss 12–15% (risk/reward ~2:1).
• Pair trade: short CVSG.L / long PETS.L (equal notional) over 3–9 months — hedge sector/regulatory beta while expressing conviction that partnership/asset-light models will command premium multiple expansion. Target relative outperformance of PETS.L by 15–25%.
• Buy 9–12 month CVSG.L put spread to cap premium cost (long put 25% OTM, short put 40% OTM) sized 1–2% notional — event hedge into CMA decision window (spring 2026) and potential near-term impairments; max loss = premium, upside if stock gaps lower on misses or unfavorable remedies.
• If seeking optionality around regulatory outcome, buy volatility: purchase a near-term straddle on CVSG.L 2–4 weeks into the CMA decision and trim on the first 20–30% realized move. This is a directional-agnostic play on elevated event risk with defined timebox.